Hanmi to Streamline Clinical Trials and Bolster Quality of Results with Medidata Cloud
August 23 2018 - 5:30PM
Business Wire
- Leading R&D focused Korean
pharmaceutical company expands use of Intelligent Platform for Life
Sciences
- Adds Edge Central Monitoring with
Machine Learning and Rave eCOA/ePRO
- Hanmi streamlines management of
clinical trial risk and mobile patient data
Full Story
Hanmi expanded its use of the Medidata Cloud, the Intelligent
Platform for Life Sciences, to improve clinical trial efficiency
and quality of results, Medidata (NASDAQ:MDSO) announced today. By
adding Edge Central Monitoring and Rave eCOA/ePRO to its current
use of Rave EDC, Hanmi will gain greater insight into clinical
trial performance and mobile patient data.
Failing to identify data anomalies during clinical trials can
hinder a study’s progress and success. Hanmi will utilize Medidata
Edge Central Monitoring to:
- Analyze clinical trial data through
machine learning, and identify errors and/or outliers
- Monitor and analyze risk during
clinical procedures
- Measure overall data consistency, and
compare across studies, indications and disease areas
“Hanmi is dedicated to providing patients with new medical
treatments through the continuous adoption of cutting-edge research
and development technology. With the expanded Medidata
relationship, we expect to enhance the efficiency of our clinical
trials and get drugs to market faster,” said an official
spokesperson of Hanmi.
Medidata is digitally transforming clinical trials
Hanmi is currently leveraging Rave EDC to manage and ingest
traditional clinical trial data. With the expansion of Medidata
eCOA/ePRO, Hanmi will:
- Seamlessly store patient reported
outcome (PRO) data collected on mobile devices
- Reduce the need for time-consuming data
cleansing of paper-based PROs
“Medidata is proud of our strong, long-time partnership with
Hanmi, one of the leading pharmaceutical companies in Korea,”
Woosung Lim, general manager of Medidata Korea said. “We’re excited
that Hanmi and over 1,000 global life science companies continue to
digitally transform their clinical trials with our advanced
analytics and machine learning solutions.”
About Medidata
Medidata is leading the digital transformation of life sciences,
with the world's most used platform for clinical development,
commercial, and real-world data. Powered by artificial intelligence
and delivered by the #1 ranked industry experts, the Intelligent
Platform for Life Sciences helps pharmaceutical, biotech, medical
device companies, and academic researchers accelerate value,
minimize risk and optimize outcomes. Medidata serves more than
1,000 customers and partners worldwide and empowers more than
100,000 certified users every day to create hope for millions of
patients. Discover the future of life sciences: www.mdsol.com
About Hanmi Pharmaceutical Co., Ltd
Since established in 1973, Hanmi Pharmaceutical has become a
Korea’s very first global pharmaceutical company through Korean
R&D strategy starting from synthesis technology development
continues to generic, IMD/FDC and innovative new drugs. Since 2015,
Hanmi has entered several license agreements with global big pharma
including Sanofi, Janssen, Genentech, Spectrum, also has been
collaborating with MSD, Sanofi-Aventis Korea, etc. on fixed dose
combination drugs related business. Furthermore, Hanmi has various
strategic partnerships with multinational companies and biotechs
through Open Innovation strategy. Currently, Hanmi is conducting
global clinical trials for developing biologics and anti-cancer new
drugs based on proprietary platform technologies 'LAPSCOVERY',
'PENTAMBODY' and 'ORASCOVERY'.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20180823005773/en/
Medidata SolutionsInvestors:Betsy Frank, +1
917-522-4620bfrank@mdsol.comorMedia:Erik Snider, +1
646-362-2997esnider@mdsol.com
Medidata Solutions (NASDAQ:MDSO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Medidata Solutions (NASDAQ:MDSO)
Historical Stock Chart
From Apr 2023 to Apr 2024